Demographics and baseline characteristics of 4 MCI studies
| Study | Placebo, n | Age, mean (SD) | Sex, male, n (%) | ApoE ε4 positive, n (%) | CSF Aβ(1–42) positive, n (%) |
|---|---|---|---|---|---|
| ADNI-MCI* | 405 | 74.2 (7.41) | 259 (64.0) | 217 (53.6) | 146 (36.0) |
| ADCS-MCI† | 264 | 72.3 (7.54) | 138 (52.3) | 138 (52.3) | |
| MCI412‡,§ | 388 | 69.8 (10.31) | 223 (57.5) | 118 (30.4) | |
| MCI415§,¶ | 103 | 73.1 (6.62) | 49 (47.6) |
ApoE, apolipoprotein E; CSF, cerebrospinal fluid; MCI, aMCI/MCI, amnestic/mild cognitive impairment.
*Alzheimer's Disease Neuroimaging Initiative MCI data base.
†Placebo group from Eisai/Pfizer trial of vitamin E and donepezil HCI (Aricept) in aMCI conducted by the Alzheimer's Disease Cooperative Study (ADCS) group.8
‡Placebo group from Eisai/Pfizer E2020-A001-412 study of donepezil in aMCI.9
§Shared data between Pfizer and Eisai.
¶Placebo group from Eisai E2020-E033-415 study of donepezil 10 mg/day in aMCI (Clinical trials identifier: NCT00403520).